BCRX BioCryst Pharmaceuticals Inc.

5.20
+0.12  (2%)
Previous Close 5.08
Open 5.10
Price To book 21.67
Market Cap 511320046
Shares 98,330,778
Volume 813,990
Short Ratio 3.63
Av. Daily Volume 1,758,569

SEC filingsSee all SEC filings

  1. 8-K - Current report 171086780
  2. 424B2 - Prospectus [Rule 424(b)(2)] 171084281
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171079043
  4. 8-K - Current report 171067344
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014199

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved September 21, 2017.
RAPIVAB (peramivir injection)
Acute uncomplicated influenza to pediatric patients
Phase 2 initiation announced August 2, 2017.
BCX7353 - ZENITH-1
Angioedema attacks in patients with hereditary angioedema (HAE)
Phase 2b data released February 2016 - primary endpoint not met
BCX4161 - OPuS-2
Hereditary angioedema
Phase 2 interim data released February 27, 2017. Top-line data released May 25, 2017. Pivotal trial to be initiated 1Q 2018.
BCX7353 - APeX-1
Reduce or eliminate attacks in HAE patients
Approved Dec 22 2014
RAPIVAB (peramivir)
INFLUENZA ACUTE

Latest News

  1. ETFs with exposure to BioCryst Pharmaceuticals, Inc. : October 17, 2017
  2. BioCryst Announces RAPIVAB® (peramivir injection) and Galidesivir Presentations at IDWeek 2017™
  3. ETFs with exposure to BioCryst Pharmaceuticals, Inc. : September 22, 2017
  4. Today's Research Reports on Stocks to Watch: Neurocrine Biosciences and Biocryst Pharmaceuticals
  5. BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017
  6. FDA OKs BioCryst's Rapivab for Pediatric Indication - Biotech Movers
  7. Can BioCryst Turn Itself Around With This FDA Approval?
  8. Have Investors Already Priced In BioCryst Pharmaceuticals Inc’s (BCRX) Growth?
  9. BioCryst’s RAPIVAB® (peramivir injection) Receives FDA Approval for a Pediatric Indication
  10. BioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
  11. BioCryst Meeting with FDA to Design Phase III Trial for BCX7353 and PDUFA Review for RAPIVAB
  12. BioCryst Pharmaceuticals Prices Public Offering of Common Stock
  13. BioCryst Pharmaceuticals Announces Secondary Offering
  14. BioCryst Pharmaceuticals Commences Public Offering of Common Stock
  15. BioCryst Pharma Sees Brief Surge on Mid-Stage Trial Win
  16. BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE
  17. BioCryst Announces Corporate Update Conference Call and Webcast

SEC Filings

  1. 8-K - Current report 171086780
  2. 424B2 - Prospectus [Rule 424(b)(2)] 171084281
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171079043
  4. 8-K - Current report 171067344
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014199
  6. 8-K - Current report 171009946
  7. 8-K - Current report 17998266
  8. EFFECT - Notice of Effectiveness 17907867
  9. SC 13G - Statement of acquisition of beneficial ownership by individuals 17892135
  10. S-8 - Securities to be offered to employees in employee benefit plans 17880787